Market News Archives

Parkinson’s Drug Milestone: Serina Therapeutics Wins FDA Support, HCW Wainwright Reaffirms Buy Rating on SER Stock ( $SER $IBB $XBI )

by John F. Heerdink, Jr. August 28, 2025 694Views 0Likes

HCW Wainwright has reiterated its Buy rating on Serina Therapeutics (NYSE American: SER), emphasizing both the company’s clinical progress and robust valuation metrics as key drivers for investor optimism. Company Snapshot and Market Performance Serina Therapeutics (SER) currently trades at $5.04 per share with a market…

Stock Buybacks Hit Historic Highs: What Wall Street’s 2026 $1.2 Trillion Spree Means for Investors – ( $AAPL $BAC $GOOG $JPM $NVDA $META $MS )

by John F. Heerdink, Jr. August 27, 2025 783Views 0Likes

U.S. corporations have crossed an extraordinary threshold in 2025, shattering records by eclipsing $1 trillion in share buybacks before the close of August—faster than any year in history. This landmark moment underscores a potent undercurrent of confidence among America’s corporate titans, driven…

How MongoDB’s Product Innovations and AI Partnerships Are Fueling a Bullish Outlook ( $MDB $QQQ )

by John F. Heerdink, Jr. August 27, 2025 545Views 0Likes

MongoDB, Inc. (MDB) is riding a wave of momentum, decisively positioning itself as a foundational enabler of the artificial intelligence revolution with robust financials, rapid customer growth, and strategic innovation initiatives. Over the past several months, a steady cadence of announcements—ranging from…

AT&T’s $23 Billion EchoStar Spectrum Deal: What It Means for 5G, Broadband, and U.S. Wireless Competition – ( $SATS $T )

by John F. Heerdink, Jr. August 27, 2025 681Views 0Likes

AT&T (T) struck a $23 billion deal this week to acquire wireless spectrum licenses from EchoStar(SATS), a move set to significantly bolster its holdings across more than 400 U.S. markets and intensify the telecom arms race nationwide. The all-cash transaction, announced Tuesday,…

Production Milestone Further Positions Modular Medical for U.S. and EU Growth – ( $MODD $LLY $MDT $PODD )

by John F. Heerdink, Jr. August 26, 2025 560Views 0Likes

Modular Medical (NASDAQ: MODD) has announced a series of transformative developments positioning the company at the forefront of diabetes technology innovation. Robust Manufacturing Momentum In August, Modular Medical completed a pivotal production milestone, finalizing over 6,000 MODD1 cartridges and seamlessly transitioning manufacturing…

Serina Therapeutics Gains FDA ‘Green Light’: Seeking to Accelerate Parkinson’s Innovation with POZ Platform – ( $SER $BMY )

by John F. Heerdink, Jr. August 25, 2025 793Views 0Likes

Serina Therapeutics (NYSE American: SER) is rapidly emerging as a compelling force in biotechnology, innovating at the intersection of neuroscience, advanced drug delivery, and capital efficiency—a combination that has resonated with investors and is gaining Wall Street momentum. The latest, game-changing press…

Reinventing Diabetes Care: Modular Medical’s Bold Bet on Simpler, Smarter Insulin Delivery – ( $MODD )

by John F. Heerdink, Jr. August 7, 2025 657Views 0Likes

Modular Medical (NASDAQ: MODD), a potential disruptor in diabetes care technology, is rapidly moving from visionary concept to tangible innovation as it propels its FDA cleared MODD1 insulin patch pump toward commercial launch. The company has recently validated its MODD1 cartridge manufacturing…

U.S.-Based GeoVax Emerges as Key Monopoly Challenger Amid $2.99B Bavarian Nordic Takeover – ($GOVX $IBB $XBI)

by John F. Heerdink, Jr. July 31, 2025 586Views 0Likes

Bavarian Nordic, a leading Danish vaccine manufacturer best known for its MVA-BN (Modified Vaccinia Ankara–Bavarian Nordic) smallpox and mpox vaccines, recently agreed to a $2.99 billion takeover by private equity firms Permira and Nordic Capital. Shareholders are being offered 233 Danish kroner…

Merck Sets Its Sights on Eyebiotech: Pharma Giant Eyes $1.3 Billion Move Into Vision Care

by John F. Heerdink, Jr. July 11, 2025 459Views 0Likes

Merck (MRK) is setting its sights on a new frontier—your eyes. The pharmaceutical heavyweight is on the verge of acquiring Eyebiotech, an ophthalmology biotech upstart, in a deal valued at a crisp $1.3 billion. If finalized, this move would mark Merck’s debut into the…

Eupraxia Advances EoE Drug Development With Phase 2b Milestone – ( $EPRX $IBB $XBI )

by John F. Heerdink, Jr. July 9, 2025 724Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) has taken a significant step in its quest to address one of gastroenterology’s most stubborn challenges: eosinophilic esophagitis (EoE). The Victoria, Canada-based biotechnology firm announced (July 8, 2025) that it has dosed the first patient in…

Market News

Your Guide To Staying Informed In The Markets